Merck & Co., Inc: Migraine Disorders trials
The registry lists 18 Migraine Disorders studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 14 have results posted.
Phase 1 6Phase 2 6Phase 3 6No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)CompletedNCT01513291Phase 2Results posted
- Study of Treatment Used for Migraine Headaches (MK-0974-076)TerminatedNCT01421277Results posted
- Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)CompletedNCT01315847Phase 1Results posted
- Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)CompletedNCT01125774Phase 2/3Results posted
- MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)TerminatedNCT00797667Phase 2Results posted
- A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)CompletedNCT00758836Phase 2Results posted
- MK3207 for Treatment of Acute Migraines (3207-005)CompletedNCT00712725Phase 2Results posted
- Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)CompletedNCT00701389Phase 1Results posted
- Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)CompletedNCT00662818Phase 3Results posted
- Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)CompletedNCT00483704Phase 3Results posted
- Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)CompletedNCT00443209Phase 3Results posted
- Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)CompletedNCT00442936Phase 3Results posted
- Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)CompletedNCT00432237Phase 3Results posted
- A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)CompletedNCT00246337Phase 2Results posted
- Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)CompletedNCT01209741Phase 1
- Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)CompletedNCT00966030Phase 1
- Bioequivalence of Two Tablet Forms of MK0974 (0974-045)CompletedNCT00965887Phase 1
- A Study of Gastric Delay in Migraine Patients (3207-003)CompletedNCT00548353Phase 1